Skip to main content
Journal cover image

Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.

Publication ,  Journal Article
Krystal, AD; Benca, RM; Rosenberg, R; Schweitzer, PK; Malhotra, A; Babson, K; Lee, L; Bujanover, S; Strohl, KP
Published in: J Psychiatr Res
November 2022

Given the high rate of depression associated with narcolepsy or obstructive sleep apnea (OSA), this analysis compared effects of solriamfetol treatment of excessive daytime sleepiness (EDS) in participants with/without a history of depression (DHx+/DHx-). This secondary analysis included data from two randomized, controlled trials in which participants were randomized to 12 weeks placebo or solriamfetol 37.5 (OSA only), 75, 150, or 300 mg/day. Efficacy/safety (combined solriamfetol doses) was summarized for DHx+/DHx-subgroups. 27.5% (65/236) with narcolepsy and 23.4% (111/474) with OSA were DHx+. In narcolepsy (DHx+ and DHx-), 40-min Maintenance of Wakefulness Test (MWT40) mean sleep latency increased (5.4 and 7.0 min), Epworth Sleepiness Scale (ESS) score decreased (3.8 and 3.5 points), and percentage of participants improved on Patient Global Impression of Change (PGI-C) was higher (31.7% and 39.4%) relative to placebo. In OSA (DHx+ and DHx-), MWT40 mean sleep latency increased (7.7 and 10.7 min), ESS decreased (3.5 and 3.7 points), and percentage of participants improved on PGI-C was higher (41.1% and 29.4%) relative to placebo. Common treatment-emergent adverse events (headache, decreased appetite, nausea, anxiety) were similar in DHx+/DHx-. This study suggests that safety and efficacy of solriamfetol for treating EDS in narcolepsy and OSA are not affected by depression history. Moreover, the findings emphasize the high prevalence of depression in people with sleep disorders and suggest that increased awareness of this association may have clinical significance.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Psychiatr Res

DOI

EISSN

1879-1379

Publication Date

November 2022

Volume

155

Start / End Page

202 / 210

Location

England

Related Subject Headings

  • Treatment Outcome
  • Sleep Apnea, Obstructive
  • Psychiatry
  • Phenylalanine
  • Narcolepsy
  • Humans
  • Double-Blind Method
  • Disorders of Excessive Somnolence
  • Depression
  • Carbamates
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Krystal, A. D., Benca, R. M., Rosenberg, R., Schweitzer, P. K., Malhotra, A., Babson, K., … Strohl, K. P. (2022). Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. J Psychiatr Res, 155, 202–210. https://doi.org/10.1016/j.jpsychires.2022.08.018
Krystal, Andrew D., Ruth M. Benca, Russell Rosenberg, Paula K. Schweitzer, Atul Malhotra, Kimberly Babson, Lawrence Lee, Shay Bujanover, and Kingman P. Strohl. “Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.J Psychiatr Res 155 (November 2022): 202–10. https://doi.org/10.1016/j.jpsychires.2022.08.018.
Krystal AD, Benca RM, Rosenberg R, Schweitzer PK, Malhotra A, Babson K, et al. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. J Psychiatr Res. 2022 Nov;155:202–10.
Krystal, Andrew D., et al. “Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.J Psychiatr Res, vol. 155, Nov. 2022, pp. 202–10. Pubmed, doi:10.1016/j.jpsychires.2022.08.018.
Krystal AD, Benca RM, Rosenberg R, Schweitzer PK, Malhotra A, Babson K, Lee L, Bujanover S, Strohl KP. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. J Psychiatr Res. 2022 Nov;155:202–210.
Journal cover image

Published In

J Psychiatr Res

DOI

EISSN

1879-1379

Publication Date

November 2022

Volume

155

Start / End Page

202 / 210

Location

England

Related Subject Headings

  • Treatment Outcome
  • Sleep Apnea, Obstructive
  • Psychiatry
  • Phenylalanine
  • Narcolepsy
  • Humans
  • Double-Blind Method
  • Disorders of Excessive Somnolence
  • Depression
  • Carbamates